Clinical Trial Update: Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating natural killer (NK) cell adback after allogeneic stem cell transplant with Campath-IH plus chemoradiation for lymphoid maligna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Campath-IH (alemtuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2012-05-22